Device-supported vs routine titration of insulin glargine 300 U/ml (Gla-300) in type 2 diabetes: efficacy and safety

被引：0
|
作者：
Flacke, F. [1 ]
Edelman, S. [2 ]
Bain, S. [3 ]
Hasslacher, C. [4 ]
Charpentier, G. [5 ]
Vespasiani, G. [6 ]
Goyeau, H. [7 ]
Woloschak, M. [8 ]
Davies, M. [9 ]
机构：
[1] Sanofi, Frankfurt, Germany
[2] Univ Calif San Diego, La Jolla, CA 92093 USA
[3] Swansea Univ, Inst Life Sci, Coll Med, Sch Med, Swansea, W Glam, Wales
[4] Diabet Inst Heidelberg, Heidelberg, Germany
[5] Sud Francilien Hosp, Dept Med, Corbeil Essonnes, France
[6] Ctr Outcomes Res & Clin Epidemiol, Pescara, Italy
[7] Sanofi, Chilly Mazarin, France
[8] Sanofi, New York, NY USA
[9] Univ Leicester, Univ Hosp Leicester, Diabet Res Ctr, Leicester, Leics, England
来源：
DIABETOLOGIA | 2017年 / 60卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
674
引用
收藏
页码：S307 / S307
页数：1
相关论文
共 50 条
  • [1] Device-Supported vs. Routine Titration of Insulin Glargine 300 U/mL (Gla-300) in T2DM: Efficacy and Safety
    Edelman, Steven
    Bain, Steve
    Hasslacher, Christoph
    Charpentier, Guillaume
    Vespasiani, Giacomo
    Flacke, Frank
    Goyeau, Harmonie
    Woloschak, Michael
    Davies, Melanie
    DIABETES, 2017, 66 : LB34 - LB34
  • [2] DEVICE-SUPPORTED VS ROUTINE (INVESTIGATOR-RECOMMENDED) TITRATION OF INSULIN GLARGINE 300 U/ML (GLA-300) IN TYPE 2 DIABETES (T2DM): EFFICACY AND TREATMENT SATISFACTION
    Flacke, F.
    Edelman, S.
    Bain, S.
    Hasslacher, C.
    Vespasiani, G.
    Goyeau, H.
    Woloschak, M.
    Davies, M.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2018, 20 : A30 - A31
  • [3] The efficacy of switching from Insulin Glargine 100 U/mL (Gla-100) to Insulin Glargine 300 U/mL (Gla-300) in patients with type 2 diabetes mellitus
    Yang, K. -H.
    Tseng, C. -T.
    Chen, L. -C.
    Chen, P. -C.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2019, 41 (01) : 310 - 310
  • [4] Safety and efficacy of a pragmatic self-titration 1 unit/day (INSIGHT) algorithm for insulin glargine 300 U/mL (Gla-300)
    Yale, J. -F.
    Harris, S. B.
    Berard, L.
    Groleau, M.
    Javadi, P.
    Stewart, J.
    DIABETOLOGIA, 2016, 59 : S440 - S440
  • [5] TAKE CONTROL: Efficacy and safety of patient-versus physician-managed titration of insulin Glargine 300 U/Ml (Gla-300) in patients with uncontrolled type 2 diabetes
    Russel-Jones, David
    Dauchy, Arnaud
    Delgado, Elias
    Dimitriadis, George
    Frandsen, Hans Albert
    Popescu, Luiza
    Schultes, Bernd
    Strojek, Krzysztof
    Harreiter, Juergen
    Bonnemaire, Mireille
    WIENER KLINISCHE WOCHENSCHRIFT, 2018, 130 : 365 - 365
  • [6] TAKE CONTROL: EFFICACY AND SAFETY OF PATIENT-VERSUS PHYSICIAN-MANAGED TITRATION OF INSULIN GLARGINE 300 U/ML (GLA-300) IN PATIENTS WITH UNCONTROLLED TYPE 2 DIABETES
    Russell-Jones, D.
    Dauchy, A.
    Delgado, E.
    Dimitriadis, G.
    Frandsen, H. A.
    Popescu, L.
    Schultes, B.
    Strojek, K.
    Bonnemaire, M.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2018, 20 : A33 - A34
  • [7] Older people with type 2 diabetes: glycaemic control and hypoglycaemia risk with new insulin glargine 300 U/ml (Gla-300)
    Stella, P.
    Aroda, V.
    Charbonnel, B.
    Ritzel, R.
    Merino-Trigo, A.
    Grisoni, M. -L.
    Sinclair, A. J.
    Yale, J. -F.
    DIABETOLOGIA, 2015, 58 : S473 - S473
  • [8] Is hypoglycaemia a modifiable patient risk in type 2 diabetes: A pooled analysis of insulin glargine 300 U/mL (Gla-300) vs 100U/mL (Gla-100) trials?
    Zhang, Q.
    Rosenstock, J.
    Gerrits, C.
    Liao, L.
    Chew, P.
    DIABETOLOGIA, 2015, 58 : S472 - S472
  • [9] Controlling glycemic variability in people living with type 1 diabetes receiving insulin glargine 300 U/mL (Gla-300)
    Mader, Julia K.
    Goelz, Stefan
    Bilz, Stefan
    Bramlage, Peter
    Danne, Thomas
    BMJ OPEN DIABETES RESEARCH & CARE, 2022, 10 (04)
  • [10] SWITCHING TO INSULIN GLARGINE 300 U/ML (GLA-300): BENEFITS VS GLA-100 BY DURATION OF PRIOR BASAL INSULIN THERAPY
    Bonadonna, R. C.
    Renard, E.
    Cheng, A.
    Fritsche, A.
    Glezer, S.
    Cali, A.
    Grisoni, M. L.
    Umpierrez, G.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2016, 18 : A31 - A31
12345